Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A bacterial infection caused by Coxiella burnetii. It is transmitted to humans by the inhalation of infected air particles or contact with fluids and feces of infected animals. Signs and symptoms include the abrupt onset of fever, headache, myalgias, and weakness.
Biomarker and diagnostic research for Q fever has been reported in the published literature.
1 FDA-approved treatment is available for Q fever, including MINOCYCLINE HYDROCHLORIDE (MINOCIN, approved 1972).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
Estimated prevalence: Unknown (Unknown prevalence).
2 clinical trials registered, 1 recruiting. Interventions under study include other interventions. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.
376 publications have been identified in PubMed for Q fever. Kisho has analyzed 196 by research type. Research spans Epidemiology / Natural History (35%), Case Report / Case Series (22%), and Basic Science / Preclinical (15%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 69 |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 5:30 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
MINOCYCLINE HYDROCHLORIDE |
— |
1972 |
Available |
Gene therapy approaches for Q fever have been reported in the published literature.
2 trials found
Patient case studies | 44 | 22% |
Laboratory research | 30 | 15% |
Research summaries | 26 | 13% |
Testing and diagnosis research | 16 | 8% |
Clinical study results | 5 | 3% |
Other research | 3 | 2% |
New treatment approaches | 3 | 2% |
Mazwi KD (2026). [PMID: 42130280](https://pubmed.ncbi.nlm.nih.gov/42130280/). *Vet Med Sci*. [Review / Meta-Analysis]
Kallu SA (2026). [PMID: 41933383](https://pubmed.ncbi.nlm.nih.gov/41933383/). *One Health Outlook*. [Review / Meta-Analysis]
PLOS One Editors (2026). [PMID: 42081446](https://pubmed.ncbi.nlm.nih.gov/42081446/). *PLoS One*. [Epidemiology / Natural History]
Holý O (2026). [PMID: 41942535](https://pubmed.ncbi.nlm.nih.gov/41942535/). *Sci Rep*. [Diagnostic / Biomarker]
Qayoom T (2026). [PMID: 41859821](https://pubmed.ncbi.nlm.nih.gov/41859821/). *Trans R Soc Trop Med Hyg*. [Epidemiology / Natural History]
de la Guía EM (2026). [PMID: 41534396](https://pubmed.ncbi.nlm.nih.gov/41534396/). *Med Clin (Barc)*. [Epidemiology / Natural History]
Corridan K (2026). [PMID: 41987320](https://pubmed.ncbi.nlm.nih.gov/41987320/). *Ir Vet J*. [Epidemiology / Natural History]
Lo SH (2026). [PMID: 42178686](https://pubmed.ncbi.nlm.nih.gov/42178686/). *Trop Doct*. [Epidemiology / Natural History]
Runge M (2026). [PMID: 42030958](https://pubmed.ncbi.nlm.nih.gov/42030958/). *Tierarztl Prax Ausg G Grosstiere Nutztiere*. [Review / Meta-Analysis]
Perfilyeva YV (2026). [PMID: 42210355](https://pubmed.ncbi.nlm.nih.gov/42210355/). *BMC Vet Res*. [Basic Science / Preclinical]